Projektbeschreibung
A novel vaccine against the SARS-CoV-2 virus
There is an ongoing race towards the development of a vaccine against the SARS-CoV-2 virus. The EU-funded Prevent-nCoV project will use proprietary technology to develop a novel and scalable vaccine with proven efficacy in an animal model. The technology uniquely combines virus-like particles (VLP) and the antigen of choice produced by any expression system. The two components are mixed under physiological conditions, leading to the high-density display of the antigen on the VLP surface. Vaccine candidates will initially be tested for their virus neutralisation capacity in vitro and in preclinical infection models before proceeding with a phase I/IIa study.
Wissenschaftliches Gebiet
- /Medizin- und Gesundheitswissenschaften/Gesundheitswissenschaften/Infektionskrankheit/RNA-Virus/Coronavirus
Programm/Programme
Thema/Themen
Aufforderung zur Vorschlagseinreichung
H2020-SC1-PHE-CORONAVIRUS-2020
Andere Projekte für diesen Aufruf anzeigen
Finanzierungsplan
RIA - Research and Innovation action
Koordinator
1165 Kobenhavn
Dänemark
Beteiligte (5)
2970 Horsholm
72074 Tuebingen
2970 Horsholm
6708 PB Wageningen
2333 ZA Leiden